Cellectis SA to Post FY2023 Earnings of $0.61 Per Share, SunTrust Banks Forecasts (CLLS)

Cellectis SA (NASDAQ:CLLS) – SunTrust Banks issued their FY2023 earnings estimates for shares of Cellectis in a research note issued on Tuesday, March 12th. SunTrust Banks analyst P. Lawson expects that the biotechnology company will post earnings of $0.61 per share for the year.

Several other research firms have also weighed in on CLLS. Zacks Investment Research lowered shares of Cellectis from a “buy” rating to a “hold” rating in a report on Monday, November 19th. ValuEngine lowered shares of Cellectis from a “hold” rating to a “sell” rating in a report on Thursday, January 24th. BidaskClub raised shares of Cellectis from a “strong sell” rating to a “sell” rating in a report on Wednesday, January 30th. Oppenheimer set a $44.00 target price on shares of Cellectis and gave the company a “buy” rating in a report on Sunday, November 25th. Finally, Citigroup cut their target price on shares of Cellectis from $37.00 to $22.00 and set a “neutral” rating for the company in a report on Monday. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and three have assigned a buy rating to the stock. Cellectis presently has an average rating of “Hold” and an average price target of $32.00.

CLLS opened at $19.02 on Friday. Cellectis has a 12-month low of $15.34 and a 12-month high of $38.85. The company has a market cap of $792.48 million, a price-to-earnings ratio of -9.85 and a beta of 1.76.

Hedge funds have recently made changes to their positions in the company. BlackRock Inc. lifted its position in Cellectis by 13.8% in the third quarter. BlackRock Inc. now owns 504,948 shares of the biotechnology company’s stock valued at $14,250,000 after buying an additional 61,235 shares during the last quarter. Morgan Stanley lifted its position in Cellectis by 25.2% in the third quarter. Morgan Stanley now owns 481,450 shares of the biotechnology company’s stock valued at $13,586,000 after buying an additional 96,847 shares during the last quarter. Sphera Funds Management LTD. lifted its position in Cellectis by 27.3% in the third quarter. Sphera Funds Management LTD. now owns 447,970 shares of the biotechnology company’s stock valued at $12,642,000 after buying an additional 96,096 shares during the last quarter. Credit Suisse AG lifted its position in Cellectis by 9.2% in the third quarter. Credit Suisse AG now owns 420,667 shares of the biotechnology company’s stock valued at $11,871,000 after buying an additional 35,363 shares during the last quarter. Finally, Macquarie Group Ltd. lifted its position in Cellectis by 15.0% in the fourth quarter. Macquarie Group Ltd. now owns 219,675 shares of the biotechnology company’s stock valued at $3,658,000 after buying an additional 28,688 shares during the last quarter. 27.62% of the stock is currently owned by hedge funds and other institutional investors.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL).

See Also: Gap Up Stocks

Earnings History and Estimates for Cellectis (NASDAQ:CLLS)

Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply